Anti-NFkB p105 / p50 antibody (ab7549)

Overview

• Product name
  Anti-NFkB p105 / p50 antibody
  See all NFkB p105 / p50 primary antibodies
• Description
  Rabbit polyclonal to NFkB p105 / p50
• Specificity
  Recognition is at the N-terminus. This antibody will "supershift " NFkB complexes containing the human p50 subunit. Control peptide ab7550 will compete only with the specific reaction of antiserum with Human NFkB p50 (NFKB1).
• Tested applications
  Suitable for: IHC-P, ELISA, WBmore details
• Species reactivity
  Reacts with: Human
  
• Immunogen

  Synthetic peptide:

  AEDDPYLGRFEQMF

  conjugated to KLH, corresponding to N terminal amino acids 2-15 of Human NFkB p50.

  Run BLAST with Run BLAST with
• Positive control
  • Purchase matching WB positive control:Recombinant Human NFkB p105 / p50 protein
• General notes
  NFkB is formed as a homo- or hetero-dimer. Subunits include p50 (NFkB1), p65 (RelA), c-Rel, RelB and p52 (NFkB2). The classic NFkB form exists as a p50-p65 heterodimer and predominates in many cell types. Many of the possible combinatorial forms of homo- and heterodimers have been identified and growing evidence indicates that different forms of NFkB have different functions in cells. Nuclear translocation of NFkB is confirmed by the use of electrophorectic mobility shift assays or by immunoblotting with nuclear extracts. The subunit composition of NFkB is confirmed by the use of antibodies that "supershift" the DNA/protein complex.

Properties

• Form
  Liquid
• Storage instructions
  Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage buffer
  pH: 7.20
  Preservative: 0.01% Sodium azide
• Purity
  Whole antiserum
• Purification notes
  This product was prepared from monospecific antiserum by delipidation and defibrination.
• Clonality
  Polyclonal
• Isotype
  IgG
• Research areas
  • Cell Biology
  • Apoptosis
  • Intracellular
  • NFkB
  • p50

  • Immunology
  • Innate Immunity
  • Macrophage / Inflamm.

  • Signal Transduction
  • Signaling Pathway
  • Nuclear Signaling
  • NFkB Pathway

  • Epigenetics and Nuclear Signaling
  • Nuclear Signaling Pathways
  • NFkB pathway

  • Epigenetics and Nuclear Signaling
  • Transcription
  • Transcription Factors

  • Cancer
  • Signal transduction
  • Nuclear signaling
  • NFkB pathway

  • Cancer
  • Cell Death
  • Apoptosis
  • Apoptotic Markers
  • NFkB
  • p50

Associated products

• Compatible Secondaries
  • Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077)
  • Goat Anti-Rabbit IgG H&L (HRP) (ab205718)
• Positive Controls
  • Human NFkB p105 / p50 peptide (ab7550)

Applications

Target

• Function
  NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
• Sequence similarities
  Contains 7 ANK repeats.
  Contains 1 death domain.
  Contains 1 RHD (Rel-like) domain.
• Domain
  The C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
  Glycine-rich region (GRR) appears to be a critical element in the generation of p50.
• Post-translational
  modifications
  While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
  Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
  Polyubiquitination seems to allow p105 processing.
  S-nitrosylation of Cys-61 affects DNA binding.
• Cellular localization
  Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.

• Target information above from: UniProt accession P19838 The UniProt Consortium
  The Universal Protein Resource (UniProt) in 2010
  Nucleic Acids Res. 38:D142-D148 (2010) .

  Information by UniProt
• Database links
  • Entrez Gene: 4790 Human
  • Omim: 164011 Human
  • SwissProt: P19838 Human
  • Unigene: 618430 Human
• Alternative names
  • DKFZp686C01211 antibody
  • DNA binding factor KBF1 antibody
  • DNA binding factor KBF1 EBP1 antibody

  • DNA-binding factor KBF1 antibody
  • EBP 1 antibody
  • EBP-1 antibody
  • EBP1 antibody
  • KBF1 antibody
  • MGC54151 antibody
  • NF kappa B antibody
  • NF kappaB antibody
  • NF kappabeta antibody
  • NF kB1 antibody
  • NFkappaB antibody
  • NFKB 1 antibody
  • NFKB p105 antibody
  • NFKB p50 antibody
  • Nfkb1 antibody
  • NFKB1_HUMAN antibody
  • Nuclear factor kappa B DNA binding subunit antibody
  • Nuclear factor kappa-B, subunit 1 antibody
  • Nuclear factor NF kappa B p105 subunit antibody
  • Nuclear factor NF kappa B p50 subunit antibody
  • Nuclear factor NF-kappa-B p50 subunit antibody
  • Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody
  • Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody
  • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody
  • p105 antibody
  • p50 antibody
  • p84/NF-kappa-B1 p98 antibody
  • Transcription factor NFKB1 antibody

  see all

Protocols

• Immunohistochemistry protocols
• Western blot protocols